Back to search results

Observational Study of Lisocabtagene Maraleucel for Follicular Lymphoma

This study is looking at the long-term safety of a treatment called lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory (R/R) follicular lymphoma (FL). This is an observational study, meaning researchers will collect information from patients who have already received liso-cel as part of their regular care. The main goal is to track any side effects over a long period. You might be able to join if you are 18 or older and have already been treated with at least one infusion of liso-cel for your FL, as approved by the FDA. The study plans to include about 300 participants. The current status of this study is unclear.

Study design
This is an observational study involving about 300 participants. It is not a randomized trial, meaning participants are not assigned to different treatment groups.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 15 years to track adverse events (side effects).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06794268

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Recruiting
Not specifiedAges 18+Observational
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
~300 participants
Updated 2025-02-24 on ClinicalTrials.gov
What's tested:Lisocabtagene maraleucel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events (AEs) of interest
Measured over Up to 15 years
+1 more outcome measured

Conditions

Follicular Lymphoma

Explore related trials

Follicular Lymphoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Participants known to be participating in investigational studies at the time of liso-cel, infusion
Participants treated with liso-cel for the treatment of R/R FL Grade 3b
Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product

What this trial measures

  • Incidence of adverse events (AEs) of interestUp to 15 years

    AEs of interest include: * Secondary malignancies * Cytokine release syndrome (CRS) Grade ≥ 3 * Neurotoxicity Grade ≥ 3 * Prolonged cytopenias * Pregnancy outcome * Tumor lysis syndrome (TLS) Grade ≥ 3 * Serious infections (ie, those requiring treatment) * Organ toxicities Grade ≥ 3 * Hemophagocytic lymphohistiocytosis (HLH)/ macrophage activation syndrome (MAS)-like toxicities * Aggravated graft-versus-host disease (GvHD)

  • Incidence of other adverse events (AEs) of interestUp to 15 years

    Other clinically important events that have not yet been identified as part of the liso-cel safety profile